Antisense oligonucleotides in cancer: Recent advances

BioDrugs

Volumn 13, Issue 3, 2000, Pages 195-216

  Lebedeva, Irina V ^a   Stein, C A ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLIC ACID; ANTISENSE OLIGONUCLEOTIDE; CYTOTOXIC AGENT; MATRIX METALLOPROTEINASE; PEPTIDE NUCLEIC ACID; PROTEIN BCL 2; TELOMERASE; UROKINASE; UROKINASE RECEPTOR;

CANCER THERAPY; CLINICAL TRIAL; FUSION GENE; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; HUMAN; MULTIGENE FAMILY; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0034044987     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200013030-00005     Document Type: Review

References (248)

1. Bishop JM. Molecular themes in oncogenesis. Cell 1991; 64: 235-48
2. Beckmann MW, Niederacher D, Schurch HG, et al. Multistep carcinogenesis of breast cancer and tumor heterogeneity. J Mol Med 1997; 75: 429-39
3. Zamechnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978; 75: 280-4
4. Stephenson ML, Zamechnik PC. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc Natl Acad Sci U S A 1978; 75: 285-8
5. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993; 261: 1004-12
6. Wagner RW, Flanagan WM. Antisense technology and prospects for therapy of viral infections and cancer. Mol Med Today 1997; 3: 31-8
7. Nellen W, Lichtenstein C. What makes an mRNA anti-senseitive. Trends Biochem Sci 1993; 18: 419-23
8. Marshall P, Thompson JB, Eckstein F. Inhibition of gene expression with ribozymes. Cell Mol Neurobiol 1994; 14: 5523-38
9. Eder PS, De Vine RJ, Dagle JM, et al. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′- exonuclease in plasma. Antisense Res Dev 1991; 1: 141-51
10. Milligan JF, Matteuchi MD, Martin JC. Current concepts in antisense drug design. J Med Chem 1993; 36: 1923-37
11. Stec WJ, Zon G, Egan W, et al. Automated solid-phase synthesis, separation and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides. J Am Chem Soc 1984; 106: 6077-9
12. Stein CA, Subashinge C, Shinozuka K, et al. Physico-chemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 1988; 16: 3209-21
13. Gao WY, Storm C, Egan W, et al. Cellular pharmacology of phosphorothioate homooligodeoxynucleotides in human cells. Mol Pharmacol 1993; 43: 45-50
14. Beltinger C, Saragovi HU, Smith RM, et al. Binding, uptake, and cellular trafficking of phosphorothioate-modified oligonucleotides. J Clin Invest 1995; 95: 1814-23
15. Iversen PL, Zhu S, Meyer A, et al. Cellular uptake and subcellular and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res Dev 1992; 2: 211-22
16. Yakubov LA, Deeva EA, Zarytova VF, et al. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc Natl Acad Sci U S A 1989; 86: 6454-8
17. Stein C, Tonkinson J, Zhang L, et al. Dynamics of internalization of phosphodiester oligonucleotides in HL60 cells. Biochem 1993; 32: 4855-61
18. Tonkinson JL, Stein CA. Patterns of intracellular compartmentalization, trafficking and acidification of 5′-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res 1994; 22: 4268-75
19. Crooke RM, Graham MJ, Cooke ME, et al. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides. J Pharmacol Exp Ther 1995; 275: 462-73
20. Bennett CF, Chiang M-Y, Chan H, et al. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol Pharmacol 1992; 41: 1023-33
21. Gottschalk S, Cristiano RJ, Smith LC, et al. Folate receptor-mediated DNA delivery into tumor-cells - potosomal disruption results in enhanced gene-expression. Gene Ther 1994; 1 (3): 185-91
22. Lee RJ, Huang L. Folate targeted, anionic liposome-entrapped polylysine-condenced DNA for tumor cell-specific gene-transfer. J Biol Chem 1996; 271 (14): 8481-7
23. Wang S, Lee RJ, Cauchon G, et al. Delivery of antisense oligodeoxyribooligonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995; 92: 3318-22
24. Zelphati O, Zon G, Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res Dev 1993; 3: 323-38
25. Chaudhiri G. Scavenger receptor-mediated delivery of antisense mini-exon phosphorothioate oligonucleotide to Leishmania-infected macrophages. Selective and efficient elimination of the parasite. Biochem Pharmacol 1997; 53: 385-91
26. Wang S, Lee RJ, Cauchon G, et al. Delivery of antisense oligodeoxyribooligonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995; 92: 3318-22
27. Zelphati O, Zon G, Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligonucleotides encapsulated in immunoliposomes. Antisense Res Dev 1993; 3: 323-38
28. Midoux P, Mendes C, Legrand A, et al. Specific gene transfer mediated by lactosylated poly-1-lysine into hepatoma cells. Nucleic Acids Res 1993; 21: 871-8
29. Zobel H-P, Kreuter J, Werner D, et al. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligonucleotides. Antisense Res Dev 1997; 7: 483-93
30. Schwab G, Chavany C, Duroux I, et al. Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutates Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci U S A 1994; 91: 10460-4
31. Tondelli L, Ricca A, Laus M, et al. Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res 1998; 26: 5425-31
32. Maruyama A, Ishihara T, Kim JS, et al. Nanoparticle DNA carrier with poly(L-lysine) grafted polysaccaride copolymer and poly(D,L-lactic acid). Bioconjug Chem 1997; 8: 735-42
33. Vinogradov S, Bronich T, Kabanov AV. Self-assembly of polyamine-poly(ethylene glycol) copolymers with phospho rothioate oligonucleotides. Bioconjugate Chem 1998; 9: 805-12
34. Wang L, Kristensen J, Ruffner DE. Delivery of antisense oligo nucleotides using HPMA polymer: synthesis of a thiol polymer and its conjugation to water-soluble molecules. Bioconjugate Chem 1998; 9: 749-57
35. Benimetskaya L, Takle G, Vilenchik M, et al. Cationic porphy rins: novel delivery vehicles for antisense oligodeoxy nucleotides. Nucleic Acids Res 1998; 26: 5410-7
36. Kukowska-Latallo JF, Bielinska AU, Johnson J, et al. Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. PNAS 1996; 93: 4897-902
37. Giles RV, Spiller DG, Tidd DD. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides. Antisense Res Dev 1995; 5: 23-31
38. Akhtar S. Antisense technology: selection and delivery of optimally acting antisense oligonucleotides. J Drug Target 1998; 5 (4): 225-34
39. McKay R, Dean MN. Inhibition of protein kinase C-α expression in mice after systemic administration of phosphorothioate. Proc Natl Acad Sci U S A 1994; 91: 1762-6
40. Plenat F. Animal models of antisense oligonucleotides: lessons for use in humans. Mol Med Today 1996; 2: 250-7
41. Monia BP, Johnston JF, Geiger T, et al. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 1996; 2: 668-75
42. Neckers L, Rosolen A, Fahmy B, et al. Specific inhibition of oncogene expression in vitro and in vivo by antisense oligonucleotides. Ann N Y Acad Sci 1992; 660: 37-44
43. Wickstrom E, Bacon TA, Wickstrom EL. Down-regulation of c-myc antigen expression in lymphocytes of Emu-c-myc transgenic mice treated with anti-c-myc DNA methylphosphonates. Cancer Res 1992; 52 (24): 61-5
44. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochem Biophys Acta 1999; 1489: 31-44
45. Tidd DM. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer che motherapy. Anticancer Res 1990; 10: 1169-82
46. Curcio LD, Bouffard DY, Scanlon KJ. Oligonucleotides as modulators of cancer gene expression. Pharmacol Ther 1997; 74 (3): 317-32
47. Dash P, Lotan I, Knapp M, et al. Selective elimination of mRNAs in vivo: complementary oligodeoxynucleotides promote RNA degradation by an RNase H-like activity. Proc Natl Acad Sci U S A 1987; 84: 7896-900
48. Crooke ST, Lemonidis KM, Neilson L, et al. Kinetic characteristics of Escherichia coli RNase Hl: cleavage of various antisense oligonucleotide-RNA duplexes. Biochem J 1995; 312: 599-608
49. McManaway ME, Neckers LM, Loke SL, et al. Tumour-specific inhibition of lymphoma growth by an antisense oligodeoxynucleotide. Lancet 1990; 335: 808-11
50. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad U S A 1993; 90: 8673-7
51. Agrawal S, Goodchild J, Civeira MP, et al. Oligodeoxynucleoside phosphoroamidates and phosphorothioates as inhibitors of human immunodeficiency virus [published erratum ap pears in Proc Natl Acad Sci USA 1989; 86: 1504]. Proc Natl Acad Sci U S A 1988; 85: 7079-83
52. Westermann P, Gross B, Hoinkis G. Inhibition of expression of SV40 virus large T-antigen by antisense oligodeoxyribonucleotides. Biochim Biophys Acta 1989; 48: 85-93
53. Baker BF, Miraglia L, Hagedorn CH. Modulation of eukaryotic initiation factor-4E binding to 5′-capped oligoribo nucleotides by modified antisense oligonucleotides. J Biol Chem 1992; 267 (16): 11495-9
54. Wu H, Macleod AR, Lima WF, et al. Identification and partial purification of human double strand RNase activity. A novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem 1998; 273: 2532-42
55. Torrence PE, Xiao W, Li G, et al. Recruiting the 2-5A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev 1997; 7: 203-6
56. Ma M, Benimetskaya L, Lebedeva I, et al. Intracellular m RNA cleavage induced via activation of RNase P by nuclease-resistant external guide sequences (EGS): a demonstration of principle. Nature Biotechnol 2000: in press
57. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990; 1049: 99-125
58. Wagner RW, Matteucci MD, Grant D, et al. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nature Biotechnol 1996; 14: 840-4
59. Woolf TM, Melton DA, Jennings CGB. Specificity of antisense oligonucleotides in vivo. Proc Natl Acad Sci U S A 1992; 89: 7305-9
60. Monia BP, Johnston JF, Ecker DJ, et al. Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 1992; 267: 19954-62
61. Monia BP, Lesnik EA, Gonzalez C, et al. Evaluation of 2'- modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem 1993; 268: 14514-22
62. Flanagan WM, Kothavale A, Wagner RW. Effects of oligonucleotide length, mismatches, and mRNA levels on C-5 propyne-modified antisense potency. Nucleic Acids Res 1996; 24: 2936-41
63. Lima WF, Monia BP, Ecker DJ, et al. Implication of RNA struc ture on antisense oligonucleotide hybridization kinetics. Biochem 1992; 31: 12055-61
64. Stull RA, Taylor LA, Szoka Jr FC. Predicting antisense oligo nucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices. Nucleic Acid Res 1992; 20: 3501-8
65. Lima WF, Brown-Driver V, Fox M, et al. Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J Biol Chem 1997; 272: 626-38
66. Ho SP, Britton DH, Stone BA, et al. Potent antisense oligodeoxynucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res 1996; 24: 1901-7
67. Ho SP, Bao YJ, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nature Biotechnol 1998; 16: 59-63
68. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nature Biotechnol 1997; 15: 537-41
69. Vickers TA, Ecker DJ. Enhancement of ribosomal frameshifting by oligonucleotides targeted to the HIV gag-pol region. Nucleic Acids Res 1992; 20: 3945-53
70. Stull RA, Zon G, Szoka Jr FC. An in vitro messenger RNA binding assay as a tool for identifying hybridization-competent antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1996; 6: 221-8
71. Dean NM, McKay R, Miraglia L, et al. Antisense oligonucleotides as inhibitors of signal transduction: development from research tools to therapeutic agents. Biochem Soc Trans 1996; 24 (3): 623-9
72. Tu G, Cao Q, Zhou F, et al. Tetranucleotide GGGA motif in primary RNA transcripts. J Biol Chem 1998; 273: 25125-31 73.
73. Sharma HW, Narayanan R. The therapeutic potential of antisense oligonucleotides. Bioessays 1995; 17: 1055-63
74. Gewirtz AM, Stein CA, Glazer PM. Facilitating oligonucleotide delivery: Helping antisense deliver on its promise. Proc Natl Acad Sci U S A 1996; 93: 3161-3
75. Stein CA, Krieg AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxy nucleotides. Antisense Res Dev 1994; 4: 67
76. Krieg AM, Yi A-K, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546-9
77. Zhao QY, Temsamani J, Iadarola PL, et al. Effect of different chemically modified oligonucleotides on immune stimulation. Biochem Pharmacol 1996; 51: 173-82
78. Vaerman JL, Moureau P, Deldime F, et al. Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood 1997; 90: 331-9
79. Guvakova MA, Yakubov LA, Vlodavsky I, et al. Phos phorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995; 270: 2620-7
80. Rockwell P, O'Connor WJ, King K, et al. Cell surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A 1997; 94 (12): 6523-8
81. Teasdale RM, Matson SJ, Fisher E, et al. Inhibition of T4 poly nucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. Antisense Res Dev 1994; 4: 295-7
82. Benimetskaya L, Loike JD, Khaled Z, et al. Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nature Med 1997; 3: 414-20
83. Perez JR, Li Y, Stein CA, et al. Sequence-independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A 1994; 91: 5957-61
84. Chavany C, Connell Y, Neckers L. Contribution of sequence and phosphorothioate content to inhibition of cell growth and adhesion caused by c-myc antisense oligomers. Mol Pharmacol 1995; 48: 738-46
85. Khaled Z, Benimetskaya L, Seltser R, et al. Multiple mechanisms may contribute to the cellular anti-adhesive effects of phosphorothioate oligonucleotides. Nucleic Acids Res 1996; 24: 737-45
86. Wang W, Chen HJ, Warshofsky M, et al. Effects of S-dC28 on vascular smooth muscle cell adhesion and plasminogen acti vator production. Antisense Nucleic Acid Drug Dev 1997; 7: 101-7
87. Benimetskaya L, Berton M, Kolbanovsky A, et al. Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF-kappaB p65) 'antisense' oligodeoxynucleotide. Nucleic Acids Res 1997; 25: 2648-56
88. Simons M, Edelman ER, DeKeyser JL, et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992; 359: 67-70
89. Vlassov VV, Pautova LV, Rykova Elu, et al. Interactions of oligonucleotides with blood serum proteins. Biokhimia 1993; 58: 1247-51
90. Bergan R, Connell Y, Fahmy B, et al. Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure. Nucleic Acids Res 1994; 22: 2150-4
91. Neckers LM, Iyer K. Nonantisense effects of antisense oligo nucleotides. In: C Stein, A Krieg, editors. Applied antisense oligonucleotide technology. New York: John Wiley, 1998: 147-59
92. Weiner GJ, Liu H-M, Woolridge JE, et al. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A 1997; 94: 10833-7
93. Krieg AM. The CpG motif: implications for clinical immunology. Bio Drugs 1998; 10 (5): 341-6
94. Ma L, Calvo F. Recent status of the antisense oligonucleotide approaches in oncology. Fundam Clin Pharmacol 1996; 10: 97-115
95. Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A 1997; 94: 2776-8
96. Holt JT, Redner RL, Nienhuis AW. An oligomer complementary to c-myc mRNA inhihits proliferation of HL-60 promyelocytic cells and induces differentiation. Molec Cell Biol 1988; 8: 963-73
97. Wickstrom EL, Bacon TA, Gonzalez A, et al. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecanucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A 1988; 85: 1028-32
98. Szczylik C, Skorski T, Malaguarnera L, et al. Inhibition of in vitro proliferation of chronic myelogenous leukemia progenitor cells by c-myb antisense oligodeoxynucleotides. Folia Histochem Cytobiol 1996; 34: 129
99. Leonetti C, IDA, Lozupone F, et al. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in mice. J Natl Cancer Inst 1996; 88: 419-29
100. Pierga JY, Magdelenat H. Applications of antisense oligonucleotides in oncology. Cell Mol Biol 1994; 40: 237-61
101. Chen L, Agrawal S, Zhou W, et al. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A 199; 95 (1): 195-200
102. Campbell JW, Pollack YF. Growth factors in gliomas; Antisense and dominant negative mutant strategies. J Neurol Oncol 1997; 35: 275-85
103. Ensoli B, Markham P, Kao V, et al. Block of AIDS-Kaposi's sarcoma cell growth, angiogenesis, and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of KS. J Clin Invest 1994; 94: 1736-46
104. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxy nucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 1996; 93: 4851-6
105. Saleh M, Stacker SA, Wilks AF. Inhibition of growth of C6glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401
106. Brysch W, Magal E, Louis JC, et al. Inhibition of p185c-erbB-2proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine kinaseactivity and strongly inhibits mammary tumor-cell proliferation. Cancer Gene Ther 1994; 1: 99-105
107. Colomer R, Lupu R, Bacus SS, et al. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 1994; 70:819-25
108. Wiechen K, Dietel M. C-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cellspreading of P185c-erbB-2-overexpressing ovarian carcinoma cells. Int J Cancer 1995; 63: 604-8
109. Daum G, Eisenmann-Tappe I, Fries HW, et al. The ins and outsof raf kinases. Trends Biochem Sci 1994; 19: 474-80
110. Basu A. A potential of protein kinase C as a target for anticancer treatment. Pharm Ther 1993; 59: 257-80
111. Dean NM, McKay R, Condon TP, et al. Inhibition of proteinkinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesionmolecule I (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994; 269: 16416-24
112. Dean NM, McKay R, Miraglia L, et al. Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of PKC-α expression. Cancer Res 1996; 15:3499-507
113. Cho-Chung YS, Clair T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancerand other cellular dysfunctional-related diseases. PharmacolTher 1993; 60: 265-88
114. Tortora G, Yokazaki H, Pepe S, et al. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. ProcNatl Acad Sci U S A 1991; 88: 2011-5
115. Yokozaki H, Budillon A, Tortora G, et al. An antisense oligonucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 1993; 53: 868-72
116. Nesterova M, Cho-Chung YS. A single-injection protein kinaseA-directed antisense treatment to inhibit tumor growth. Nature Med 1995; 1: 528-33
117. Holt JT. A 'sensless' immune response to DNAs Nature Med 1995; 1: 407-8
118. Indolfi C, Chiariello M, Avvedimento EV. Selective gene therapy for proliferative disorders: Sense and antisense. Nature Med 1996; 2 (6): 634-5
119. Lefebvre d'Hellencourt C, Diaw L, Guenounou M. Immunomodulation by cytokine antisense oligonucleotides. Eur Cytokine Netw 1995; 6 (1): 7-19
120. Hung WC, Huang JS, Chuang LY. Antisense oligodeoxynucleotides targeted against different regions of cyclin D1mRNA may exert different inhibitory effects on cell growthand gene expression. Biochem Biophys Res Commun 1996;220 (3): 719-23
121. Cagnoli M, Barbieri F, Bruzzo C, et al. Control of cyclin D1 expression by antisense oligonucleotides in three ovarian cancer cell lines. Gynecol Oncol 1998; 70 (3): 372-7
122. Mukhopadhyay T, Roth JA. Antisense regulation of oncogenesin human cancer. Crit Rev Oncogen 1996; 7 (3-4): 151-90
123. Ju J, Kane SE, Lenz H-J, et al. Desensitization and sensitization of cells to fluoropyrimidines with different antisenses directed against thymidilate synthase messenger RNA. ClinCancer Res 1998; 4: 2229-36
124. Kitajima I, Shinohara T, Bilakovics J, et al. Ablation of transplanted HTLV-1 Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 1992; 258: 1792-5
125. Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms Tumor Gene) antisense oligonucleotides: Implications for the involvement ofWT1 in leukemogenesis. Blood 1996; 7: 2878-84
126. Skilling JS, Squatrito RC, Connor JP, et al. p53 gene mutationanalysis and antisense-mediated growth inhibition of humanovarian carcinoma cell lines. Gynecol Oncol 1996; 60 (1):72-80
127. Hirota Y, Horiuchi T, Akahane K. p53 Antisense oligonucleotide inhibits growth of human colon tumor and normal celllines. Jpn J Cancer Res 1996; 87 (7): 735-42
128. Ishii H, Igarashi T, Saito T, et al. Retinoblastoma protein expressed in human non-Hodgkin's lymphoma cells generates resistance against radiation-induced apoptosis. Am J Hematol1997; 55 (1): 46-8
129. Barton CM, Lemoine NR. Antisense oligonucleotides directed against p53 have antiproliferative effects unrelated to effects on p53 expression. Br J Cancer 1995; 71 (3): 429-37
130. Del Rosso M, Fibbi G, Pucci M, et al. Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer. Clin Exper Rheumatol 1998; 16 (4): 389-93
131. Chambers AF, Matrisian ML. Changing views of the role ofmatrix metalloproteinases in metastasis. J Natl Cancer Inst1997; 89: 1260-70
132. Quattrone A, Fibbi G, Anichini E, et al. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptorgene expression. Cancer Res 1995; 55: 90-5
133. Wilhelm O, Schmitt M, Hohl S, et al. Antisense inhibition ofurokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995; 13: 296-302
134. Lin M, Hultquist KL, Oh DH, et al. Inhibition of collagenasetype 1 expression by psoralen antisense oligonucleotides indermal fibroblasts. FASEB J 1995; 9: 1371-7
135. Hasegawa S, Koshikawa N, Momiyama N, et al. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer1998; 76: 812-6
136. Delong RK, Miller phosphorothioate. Inhibition of human collagenase activity by antisense oligonucleoside methylphosphonates. Antisense Nucleic Acids Drug Dev 1996; 6:273-80
137. Momiyama N, Koshikawa N, Ishikava T, et al. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro. Mol Carcinog 1998; 22: 57-63
138. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994; 266: 2011-5
139. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science 1995; 269: 1236-41
140. Norton JC, Piatyszek MA, Wright WE, et al. Inhibition of human telomerase activity by peptide nucleic acids. Nature Biotechnol 1996; 14: 615-9
141. Kondo S, Kondo Y, Li G, et al. Targeted therapy of humanmalignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998; 16 (25):3323-30
142. Daley GQ, Van Etten RA, Baltimore D. Induction of chronicmyelogenic leukemia in mice by the p210bcr-abl gene of the Philadelphia chromosome. Science 1990; 247: 824-30
143. Kirkland MA. O'Brien SG, McDonald C, et al. BCR-ABL antisense purging in chronic myeloid leukaemia. Lancet 1993;342: 614
144. Szczylik C, Skorski T, Nicolaides NC, et al. Selective inhibitionof leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253 (5019): 562-5
145. Skorski T, Nieborowska-Skorska M, Nicolaides NC, et al. Suppression of Philadelphial leukemia cell growth in mice byBCR-ABL antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1994; 91: 4504-8
146. O'Brien SG, Kirkland MA, Melo JV et al. Antisense BCR-ABLoligomers cause non-specific inhibition of chronic myeloidleukemia cell lines. Leukemia 1994; 8: 2156-62
147. Bergan RC, Kyle E, Connell Y, et al. Inhibition of protein-tyrosine kinase activity in intact cells by the aptameric action of oligodeoxynucleotides. Antisense Res Dev 1995; 5: 33-8
148. Smetsers TFCM, van de Locht LTF, Pennings AHm, et al. Phosphorothioate BCR-ABL antisense oligonucleotides inducecell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 1995; 9: 118-30
149. Anderegg B, Horstmann M, Kabisch H. Effects of anti-tal-1 oligodeoxynucleotides in T-ALL cell lines. Cancer Gene Ther 1997; 4 (2): 84-90
150. Akao Y, Mizoduchi H, Misiura K, et al. Antisenseoligodeoxyribonucleotide against the MLL-LTG19 chimerictranscript inhibits cell growth and induces apoptosis in cellsof an infantile leukemia cell line carrying the t(11; 19) chromosomal translocation. Cancer Res 1998; 58 (17): 3773-6
151. Toretsky JA, Connell Y, Neckers L, et al. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997; 31 (1-2): 9-16
152. Mitani K, Ogawa S, Tanaka T, et al. Growth inhibition of leukaemic cells carrying the t (3; 21) by the AML1/EVI-1-specific antisense oligonucleotide. Br J Haematol 1995; 90(3): 711-4
153. Bernasconi M, Remppis A, Fredericks WJ, et al. Induction of apoptosis in rhabdomyosarcoma cells through down-regulationof PAX proteins. Proc Natl Acad Sci U S A 1996; 93 (23):13164-9
154. Hockenbery D, Nunez G, Milliman C. et al. Bcl-2 is an innermitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-6
155. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995; 7: 541-6
156. Miyashita T, Reed JC. Bcl-2 gene transfer increases relativeresistance of S49.1 and Wehi7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992; 52: 5407-11
157. Reed JC, Stein C, Subashinge C, et al. Antisense-mediated inhibition of bcl-2 protooncogene expression and leukemic cells growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res 1990;50: 6575-9
158. Smith MR, Abubakr Y, Mohammad R, et al. Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin'slymphoma cell line WSU-FSCCL. Cancer Gene Ther 1995;2; 207-12
159. Cotter FE, Johnson P, Hall P, et al. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene 1994; 9: 3049-55
160. Janicek MF, Sevin BU, Nguen HN, et al. Combination anti-genetherapy targeting c-myc and p53 in ovarian cancer cell lines. Gynecol Oncol 1995; 59 (1): 87-92
161. Skorski T, Nieborowska-Skorska M, Campbell K, et al. Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes. J Exp Med 1995; 182 (6): 1645-53
162. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Antisense oligodeoxynucleotide combination therapy of primarychronic myelogenic leukemia blast crisis in SCID mice.Blood 1996; 88 (3): 1005-12
163. Sawyers CLThe role of myc in transformation by BCR-ABL. Leuk Lymphoma 1993; 11 Suppl. 1: 45-6
164. Rubinstein M, Mirochnik Y, Chou P, et al. Antisense oligonucleolide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 1996; 62 (3):194-200
165. Normanno N, Bianco C, Damiano V, et al. Growth inhibition ofhuman colon carcinoma cells by combination of anti-epidermal growth factor-related growth factor antisense oligonucleotides. Clin Cancer Res 1996; 2 (3): 601-9
166. Smith JB, Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murineB-cell lymphoma transplant model. J Natl Cancer Inst 1998;90: 1146-54
167. Maran A, Maitra RK, Kumar A, et al. Blockage of NF-κB signaling by selective ablation of an mRNA target by 2-5A antisense chimeras. Science 1994; 265: 789-92
168. Altmann K-H, Fabbro D, Dean NM, et al. Second-generationantisense oligonucleotides: structure-activity relationshipsand the design of improved signal-transduction inhibitors.Bichem Soc Trans 1996; 24 (3): 630-7
169. Agrawal S, Zhao Q. Mixed backbone oligonucleotides: Improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev 1998; 8: 135-9
170. Agrawal S, Jiang Z, Zhao Q, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies. Proc Natl Acad Sci U S A 1997; 94:2620-5
171. Wagner RW. Gene inhihition using antisense oligodeoxynucleotides. Nature 1994; 372: 333-5
172. Flanagan WM, Wagner RW, Grant D, et al. Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nature Biotech 1999; 17: 48-52
173. Clark RE, Giles RV, Green JA, et al. Optimization of antisense oligodeoxynucleotide structure for targeting chronic myeloid leukemia (CML). Blood 1994; 84 Suppl. 1: 156a
174. Knudsen H, Nielsen PE. Application of peptide nucleic acid incancer therapy. Anti-Cancer Drugs 1997; 8 (2): 113-8
175. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24
176. Stewart AJ, Canitrot Y, Baracchini E, et al. Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol 1996; 51: 461-9
177. Azuma E, Hiratake S, Nishiguchi Y, et al. In vivo treatment ofmultidrug-resistant murine leukemia with antisense MDR1 oligodeoxynucleotides. Blood 1994; 84 Suppl. 1: 43a
178. Hiratake S, Azuma E, Nishiguchi Y, et al. Treatment of multi-drug-resistant murine leukemia with antisense mdr1 oligonucleotides. Biochem Pharmacother 1997; 51 (6-7): 276-83
179. Nakashima E, Matsushita R, Negishi H, et al. Reversal of drugsensitivity in MDR subline of P388 leukemia by gene-targeted antisense oligonucleotide. J Pharm Sci 1995; 84: 1205-9
180. Sola JE, Colombani PM. Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdr1 mRNA. Ann Surg Oncol 1996; 3: 80-5
181. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line cell line by mdr-1 antisense oligonudeotides. Cancer Res 1996; 56:4332-7
182. Li X, Smyth AP, Barrett DJ, et al. Sensitization of multidrug-resistant human leukemia cell with MDR 1-targeted antisense and inhibition of drug-mediated MDR1 induction. Leukemia 1997; 11 (7): 950-7
183. Motomura S, Motoji T, Takanashi M, et al. Inhibition of P-glycoprotein and recovery of drug sensitivity of human acute leukemic blast cells by multidrug resistance gene (mdr1) antisense oligonucleotides. Blood 1998; 91 (9): 3163-71
184. Alahari SK, Dean NM, Fisher MH, et al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein byphosphorothioate and 5′-cholesterol-conjugated phosphorothioate antisense oligonucleotides. Mol Pharmacol 1996; 50(4): 808-9
185. Alahari SK, DeLong R, Fisher MH, et al. Novel chemically modified oligonucleotides provide potent inhihition of P-glycoprotein expression. J Pharmacol Exp Ther 1998; 286 (1): 419-28
186. Nieborowska-Skorska M, Nakashima M, Ratajczak M, et al. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approachfor tumor treatment? Folia Histochem Cytobiol 1994; 32 (1):35-40
187. Skorski T, Nieborowska-Skorska M, Barletta C, et al. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr-abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 1993; 92: 194-202
188. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60:23-32
189. Campos L, Sabido O, Rouault JP, et al. Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukemic cells. Blood 1994; 84: 595-60
190. Zhu YM, Bradbury DA, Ressell NH. Wild-type p53 is requiredfor apoptosis induced by growth factor deprivation in factor-dependent leukemic cells. Br J Cancer 1994; 69: 468-72
191. Kitada S, Takayama S, De Riel K, et al. Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression. Antisense Res Dev 1994;4: 71-9
192. Keith FJ, Bradbury DA, Zhu YM, et al. Inhibition of bcl-2 withantisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to ara-C. Leukemia 1995; 9: 131-8
193. Campbell MJ, Dawson M, Koeffler HP. Growth inhibition of DU-145 prostate cancer cells by a bcl-2 antisense oligonucleotide is enhanced by N-(2-hydroxyphenyl)all-trans retinamide. Br J Cancer 1998; 77: 739-44
194. Zangemeister-Wittke U, Schenker T, Luedke GH, et al. Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer 1998; 78: 1035-42
195. Lebedeva I, Rando R, Ojwang J, et al. Bcl-xL in prostate cancer cells: effects of overexpression and downregulation on chemosensitivity. J Biol Chem, submitted
196. Ackermann EJ, Taylor JK, Narayana R, et al. The role of anti-apoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J Biol Chem 1999; 274: 11245-52
197. Mizutani Y, Fukumoto M, Bonavida B, et al. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide. Cancer 1994; 74: 2546-54
198. Van Waardenburg RC, Prins J, Meiler C, et al. Effects of c-myc oncogene modulation on drug resistance in human small-cell lung carcinoma cell lines. Anticancer Res 1996; 16 (4A):1963-70
199. Citro G, D'Agnano I, Leonetti C, et al. c-myc Antisense oligonucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice. Cancer Res 1998, 58: 283-9
200. Del Buffalo D, Cucco C, Leonetti C, et al. Effect of cisplatinand c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. Br J Cancer 1996; 74: 387-93
201. Leszczynski D, Zhao Y, Luokkamaki M, et al. Apoptosis of vascular smooth muscle cells. Amer J Pathol 1994; 145:1265-70
202. Geiger T, Muller M, Dean NM, et al. Antitumor activity of a PKC-α antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice. Anticancer Drug Des 1998; 13: 35-45
203. Tortora G, Caputo R, Damiano V, et al. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc Natl Acad Sci U S A 1997; 94: 12586-91
204. Ciardello F, Caputo R, Bianco R, et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 1998; 90 (14): 1087-94
205. De Luca A, Selvam MP, Sandomenico C, et al. Antisense oligonucleotides directed against EGF-related growth factors enhance anti-proliferative effect of conventional anti-tumor drugs in human colon-cancer cells. Int J Cancer 1997; 73 (2): 277-82
206. Soldatenkov VA, Dritchillo A, Wang FH, et al. Inhibition of raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamos carcinoma cells to gamma-radiation. Cancer J Sci Am 1997; 3 (1): 13-20
207. Ohnishi T, Taki T, Hiraga S, et al. In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene. Biochem Biophys Res Commun 1998; 245 (2): 319-24
208. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancercells. J Natl Cancer Inst 1998; 90 (13): 978-85
209. Mizushima Y, Kashii T, Kobayashi M. Reduction of cisplatin cytotoxicity on human lung cancer cell lines with N-myc amplification by pretreatment with n-myc antisense oligodeoxynucleotides. Anticancer Res 1995; 15 (1): 37-43
210. Blagosklonny MV, Neckers LM. Oligonucleotides protect cells from the cytotoxicity of several anti-cancer chemotherapeutic drugs. Anticancer Drugs 1994; 5 (4); 437-42
211. Black LE, Degeorge JJ, Cavagnaro JA, et al. Regulatory considerations for evaluating the phrmacology and toxicology of antisense drugs. Antisense Res Dev. 1993; 3: 399-404
212. Calabretta B, Skorski T. Targeting c-myc in leukemia. Anticancer Drug Des 1997; 12: 373-81
213. Gewirtz AM. Antisense oligonucleotide therapeutics for humanleukemia. Curr Opin Hematol 1998; 5: 59-71
214. Monia BP. First- and second generation antisense inhibitors targeted to human c-raf kinase: in vitro and in vivo studies. Anticancer Drug Des 1997; 12: 327-39
215. Nesterova M, Cho-Chung YS. A single-injection protein-kinase A-directed antisense treatment to inhibit tumor growth. Nature Med 1995; 1: 528-33
216. Cowsert LM. In vitro and in vivo activity of antisense inhibitors of ras: potential for clinical development. Anticancer Drug Des 1997; 12: 359-71
217. Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 1997;349: 1137-41
218. Henry SP, Monteith D, Bennett F, et al. Toxicological properties of chemically modified antisense inhibitors of PKC-alpha and C-raf kinase. Anticancer Drug Des 1997; 12: 409-420
219. Monteith DK, Henry SP, Howard RB, et al. Immune stimulation - a class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des 1997; 12: 421-32
220. Sarmiento UM, Perez JR, Becker JM. In vivo toxicologicaleffects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev 1994; 4: 99-107
221. Srinivasan SK, Tewary HK, Iversen PL. Characterization of binding sites, extent of binding, and drug interactions of oligonucleotides with albumin. Antisense Res Dev 1995; 5: 271-7
222. Cossum PA, Sasmor H, Dellinger D, et al. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats. J Pharmacol Exp Ther 1993; 267 (3): 1181-90
223. Iversen PL, Copple BL, Tewary HK. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. Toxicol Lett 1995; 82-3: 425-30
224. Saijo Y, Perlaky L, Wang H, et al. Pharmacokinetics, tissuedistribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol Res 1996; 6: 243-9
225. Zhang R, Diasio RB, Lu Z, et al. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent forhuman immunodeficiency virus type-1. Biochem Pharmacol 1995; 49 (7): 929-39
226. Galbraith WM, Hobson WC, Giglas PC, et al. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev 1994; 4: 201-7
227. Boral AL, Dessain S, Chabner BA. Clinical evaluation of biologically targeted drugs: Obstacles and opportunities. Cancer Chemother Pharmacol 1998, 42 Suppl.: S3-S21
228. Ho PTC, Parkinson DR. Antisense oligonucleotides as therapeutics for malignant diseases. Sem Oncol 1997; 24: 187-202
229. Ziegler A, Luedke GH, Fabbro D, et al. Induction of apoptosisin small cell lung cancer cells by an antisense oligodeoxynucleotide targeting the bcl-2 coding sequence. J Natl Cancer Inst 1997; 89: 1027-36
230. Gewirtz AM. The c-myb protooncogene: a novel target for human gene therapy. Cancer Treat Res 1996; 84: 93-112
231. Burgess TL, Fisher EF, Ross SL, et al. The antiproliferativeactivity of c-myb and c-myc antisense oligonucleotides is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 1995; 92: 4051-5
232. Castier Y, Chemla E, Nierat J, et al. The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is nonspecific. J Cardiovasc Surg (Torino) 1998; 39: 1-7
233. Luger SM, Ratajczak MZ, Stadtmauer EA, et al. Autografting for chronic myelogenous leukemia (CML) with c-myb antisense oligodeoxynucleotide purged bone marrow: a preliminary report [abstract]. Blood 1994; 84 Suppl. 1: 151a
234. Gewirtz AM, Luger S, Sokol D, et al. Oligodeoxynucleotide therapeutics for human myelogenous leukemia: Interim results [abstract]. Blood 1996; 88 Suppl. 1: 270a
235. De Fabritius P, Amadori S, Petti MC, et al. In vitro purging with BCR-ABL antisense oligodeoxynucleotides does not preventhaematologic reconstitution after autologous bone marrow transplantation. Leukemia 1995; 9: 662-4
236. De Fabritius P, Petti MC, Montefusco E, et al. BCR-ABL antisense oligonucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Blood 1998; 91 (9): 3156-62
237. Bishop MR, Iversen PL, Bayever E, et al. Phase I trial of anantisense oligonucleotide OL(1)53 in hematologic malignancies. J Clin Oncol 1996; 14: 1320-6
238. Lowe SW, Bodis S, McClatchey, et al. p53 status and the efficacy of cancer therapy in vivo. Science 1994; 266: 807-10
239. Bayever E, Haines KM, Iversen PL, et al. Selective cytotoxicityto human leukemic myeloblasts produced by oligodeoxyribonucleotide phosphorothioates complementary to p53 nucleotide sequences. Leuk Lymphoma 1994; 12: 223-31
240. Bishop MR, Jackson JD, Tarantolo SR, et al. Ex vivo treatment of bone marrow with phosphorothioate oligonucleotide OL(1)p53 for autologous transplantation in acute myelogenous leukemia and myelodysplastic syndrome. J Hematother 1997; 6 (5): 441-6
241. Nemunaitis J, Eckhardt G, Dorr A, et al. Phase I evaluation of CGP 64128A, an antisense inhibitor of protein kinase C-α.(PKC-α), in patients with refractory cancer [abstract 870]. Proc Am Soc Clin Oncol 1997: 16
242. Sikic BI, Yuen AR, Halsey J, et al. A phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521) delivered by 21 day continuous intravenous infusion [abstract 741]. Proc Am Soc Clin Oncol 1997: 16
243. Dean NM, Lemonidis K, McKay R, et al. The use of antisense oligonucleotides to inhibit expression of isozymes of protein kinase C. In: Stein CA, Krieg A, editors. Applied antisense oligonucleotide technology. New York: Wiley-Liss, 1998:193-205
244. Yuen AR, Halsey J, Fisher GA, et al. Phase I study of an antisense oligonucleotide to protein kinase C-α (ISIS 3521/CGP64128A) in patients with cancer Clin Cancer Res 1999; 5:3357-63
245. Holmlund J, Nemunaitis J, Schiller J, et al. Phase I trial of c-rafantisense oligonucleotide ISIS 5132 (CGP 69846 A) by 21-day continuous intravenous infusion (CIV) in patients with advanced cancer [abstract]. Proc Am Soc Clin Oncol 1998; 17: 811
246. O'Dwyer PJ, Stevenson JP, Gallagher M, et al. Phase I/pharmacokinetic/pharmacodynamic trial of raf-1 antisense oligonucleotide (ISIS 5132, CGP 69846 A) [abstract]. Proc Am Soc Clin Oncol 1998; 17: 810
247. Chen G, Oh S, Monia BP, et al. Antisense oligonucle otidesdemonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996; 271: 28259-65
248. Bacon TA, Wickstrom E. Walking along human c-myc mRNAwith antisense oligonuclotides: maximum efficacy at the 5prime;-cap region. Oncogene Res 1991; 6: 13-9